Dingdang Health Technology Group Ltd. (Dingdang Health) filed a Next Day Disclosure Return with the Hong Kong Stock Exchange on 30 March 2026, detailing its latest share capital position and ongoing buy-back activity.

As of the close of business on 30 March 2026, Dingdang Health’s issued share capital remained unchanged at 1.32 billion ordinary shares. No treasury shares were recorded.

Latest daily purchase • On 30 March 2026 the company bought back 87,500 shares on the Exchange at prices ranging between HK$0.85 and HK$0.89, for a total consideration of HK$76,807.50. • All shares repurchased are earmarked for cancellation.

Cumulative repurchases pending cancellation • Between 25 November 2025 and 30 March 2026, the company repurchased 27.64 million shares that have not yet been cancelled. • The aggregate volume represents 2.09 % of the issued shares outstanding on 28 May 2025, the date when the current buy-back mandate was approved. • Based on disclosed per-share prices, the total cash outlay for these repurchases amounts to approximately HK$29.78 million, implying an average cost of roughly HK$1.08 per share. • Once these shares are cancelled, the issued share count would fall to about 1.29 billion.

Repurchase mandate utilisation • The existing mandate authorises Dingdang Health to repurchase up to 131.95 million shares. • After the 27.64 million shares already bought, around 104.31 million shares—equal to roughly 7.9 % of current issued capital—remain available under the mandate.

Issuance moratorium Under Hong Kong Listing Rule 10.06(3)(a), Dingdang Health is restricted from issuing new shares until 29 April 2026, 30 days after the most recent buy-back.

All repurchases were executed in compliance with Hong Kong Listing Rules, relevant regulations and the company’s board authorisation.